NEUMUNE Trademark

Trademark Overview

On Monday, March 31, 2003, a trademark application was filed for NEUMUNE with the United States Patent and Trademark Office. The USPTO has given the NEUMUNE trademark a serial number of 78231954. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, May 17, 2013. This trademark is owned by Hollis-Eden Pharmaceuticals, Inc.. The NEUMUNE trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for protection against and treatment of side effects of radiation, radio- and chemotherapeutic treatments, and other diseases and disorders, and also immune modulation
neumune

General Information

Serial Number78231954
Word MarkNEUMUNE
Filing DateMonday, March 31, 2003
Status710 - CANCELLED - SECTION 8
Status DateFriday, May 17, 2013
Registration Number3154700
Registration DateTuesday, October 10, 2006
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, October 11, 2005

Trademark Statements

Goods and Servicespharmaceutical preparations for protection against and treatment of side effects of radiation, radio- and chemotherapeutic treatments, and other diseases and disorders, and also immune modulation

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, May 17, 2013
Primary Code005
First Use Anywhere DateWednesday, March 2, 2005
First Use In Commerce DateWednesday, March 2, 2005

Trademark Owner History

Party NameHollis-Eden Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NameHollis-Eden Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
Party NameHollis-Eden Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events

Event DateEvent Description
Friday, May 17, 2013CANCELLED SEC. 8 (6-YR)
Tuesday, October 10, 2006REGISTERED-PRINCIPAL REGISTER
Wednesday, August 30, 2006LAW OFFICE REGISTRATION REVIEW COMPLETED
Friday, August 25, 2006ASSIGNED TO LIE
Friday, August 18, 2006ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, July 27, 2006STATEMENT OF USE PROCESSING COMPLETE
Thursday, July 27, 2006EXTENSION 1 GRANTED
Friday, June 30, 2006USE AMENDMENT FILED
Friday, June 30, 2006EXTENSION 1 FILED
Friday, June 30, 2006TEAS EXTENSION RECEIVED
Friday, June 30, 2006TEAS STATEMENT OF USE RECEIVED
Tuesday, January 3, 2006NOA MAILED - SOU REQUIRED FROM APPLICANT
Thursday, November 3, 2005TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, October 11, 2005PUBLISHED FOR OPPOSITION
Monday, September 26, 2005ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, September 26, 2005TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, September 21, 2005NOTICE OF PUBLICATION
Monday, August 29, 2005LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, August 26, 2005ASSIGNED TO LIE
Monday, August 22, 2005APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, January 24, 2005REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, July 22, 2004REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, June 30, 2004AMENDMENT FROM APPLICANT ENTERED
Wednesday, June 30, 2004CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, June 28, 2004AMENDMENT FROM APPLICANT ENTERED
Monday, June 28, 2004CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 30, 2004PAPER RECEIVED
Monday, June 28, 2004PAPER RECEIVED
Thursday, September 25, 2003LETTER OF SUSPENSION E-MAILED
Thursday, September 25, 2003ASSIGNED TO EXAMINER

Related Keywords

neumune diseases other treatments disorders also modulation immune chemotherapeutic radio against